If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...

Robert Ford’s comments come as new CGMs and insulin pumps continue to roll out in the diabetes tech space, including over-the-counter glucose sensors.

Normoglycemic individuals spent 87% of their daily time in in the “tight range” of glucose levels (70-140 mg/dL) and the remainder above 140 mg/dL.

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

In recent years, digital health has become a new development trend in the global health and medical industry. By using ...

DexCom, Inc. (NASDAQ:DXCM) has also consistently beat EPS estimates in the last 4 quarters. The stock has received an average ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

Not everyone in the health field is so bullish on the prospects of CGMs for everyone, and question whether digging in too ...

Ultimately, the right stocks for your portfolio will depend on numerous factors, including your risk tolerance level, ...

Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...